Seock-Ah Im

Jan 21, 2025 | nature.com | Fatima Cardoso |Heather L. McArthur |Javier Cortés |Nadia Harbeck |Melinda L. Telli |David W. Cescon | +3 more

AbstractAddition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer remains unclear.

Sep 11, 2024 | nature.com | Seock-Ah Im |Javier Cortés |David W. Cescon |Norikazu Masuda |Toshimi Takano |Chiun-Sheng Huang | +6 more

AbstractIn the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) and programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 tumors.

Aug 14, 2024 | nature.com | Seock-Ah Im

Recent advances in genome sequencing technologies have enabled a better understanding of genetic alterations in both cancer and non-neoplastic cells. Breast cancer is commonly accompanied by benign breast lesions (BBLs) in the adjacent parenchyma, and it has long been reported that a subset of such BBLs already have acquired genetic alterations such as 1q gains, 16q losses and PI3K–AKT pathway mutations.

Aug 9, 2024 | cancernetwork.com | Lowell L Hart |Seock-Ah Im |Sara M. Tolaney |Mario Campone |Timothy J. Pluard |Berta Sousa | +6 more

BackgroundRibociclib plus endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA (ML) trials in patients with hormone receptor–positive/HER2-negative (HER2+/HER2–) advanced breast cancer (ABC). Here, we report efficacy, safety, and quality of life in elderly patients in the ML trials. MethodsData were pooled from ML-2, -3, and -7 for patients treated with ribociclib plus ET or placebo plus ET.